Skip to main content

Table 1 Clinical characteristics of the cohort (n = 200)

From: Reduced oxidized LDL in T2D plaques is associated with a greater statin usage but not with future cardiovascular events

  All No T2D (n = 129) T2D (n = 71)
Age (years) 69.3 (SD 8.6) 69 (SD 8.8) 70 (SD 8.3)
Sex–Males (%) 134 (67%) 86 (67%) 48 (68%)
Smoking- current/non smokers (%) 65/40 (33/20) 44/24 (34/19) 21/16 (30/23)
BMIa 27 (SD 3.9) 26 (SD 3.7) 28 (SD 3.9)***
Degree of stenosis (%) 90 (IQR 80-95) 90 (IQR 80-95) 90 (IQR 75-95)
Hypertension (%) 147 (74) 94 (73) 53 (75)
hsCRP (mg/L)b 3.9 (IQR 2.0-6.6) 3.8 (IQR 2-6.7) 4.2 (IQR 1.9-6.6)
HbA1c (mmol/mol)e 44 (IQR 38-56) 39 (IQR 36-41) 56 (IQR 47-66)***
Plasma lipoproteins (mmol/L)
 Total cholesterol 4.4 (SD 1.1) 4.6 (SD 1.1) 4.2 (SD 1.1)*
 LDLc 2.5 (IQR 1.9-3.2) 2.6 (IQR 2.0-3.3) 2.2 (IQR 1.6-3.0)**
 HDLd 1.1 (IQR 0.9-1.3) 1.1 (IQR 0.9-1.3) 1.0 (IQR 0.8-1.3)
 Triglycerides 1.3 (IQR 1.0-1.8) 1.2 (IQR 0.9-1.7) 1.6 (IQR 1.0-2.1)**
Blood glucose lowering treatment, n(%)
 Life style changes 11 (6%) 11 (15%)
 Oral glucose lowering treatment 37 (19%) 37 (52%)
 Insulin 22 (11%) 22 (31%)
 Insulin and oral glucose lowering 12 (6%) 12 (17%)
Blood pressure lowering treatment, n(%)
 RAAS inhibitor 101 (51%) 58 (45%) 43 (61%)*
 Beta blocker 98 (49%) 59 (46%) 39 (55%)
Statin treatment, n(%) 164 (82%) 100 (78%) 64 (90%)*
  1. Categorical variables are expressed in total amount and percentages. Continuous variables as median and interquartile range (IQR) or mean and standard deviation (SD)
  2. aBMI Body mass index
  3. bhsCRP high sensitive CRP
  4. cLDL Low-density lipoprotein cholesterol
  5. dHDL High-density lipoprotein
  6. e HbA1c hemoglobin A1c, was available for 62% (n = 124) of the cohort. Hypertension defined as: anti-hypertensive treatment or systolic pressure > 140 mmHg. Level of significance between no diabetes and T2D patients is marked by *p < 0.05, **p < 0.01 and ***p < 0.005